Cureus · 2026
Maternal Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination in Panama: A Retrospective Follow-Up Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luca Quintero Ana, DeAntonio Rodrigo, Fernandez Camargo Isaac, Peralta Alvarado Ana, Escobar Luis, Ricci Perez Belen, Flores Luis Alberto, Gadea Cynthia, Barrios Sofia, Guillen Emmanuel, De Avila Abigail, Sevillano Giraldez Jaime Ricardo
Аннотация
BACKGROUND: Panama introduced routine maternal bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination (Abrysvo, Pfizer Inc., New York, NY) in July 2025. We described common retrospectively self-reported reactions and maternal, perinatal, and neonatal conditions among the first 200 eligible recipients enrolled in active follow-up.
METHODS: This retrospective descriptive cohort included women aged 18 years or older who received RSVpreF at 32.0-36.6 weeks of gestation from July through December 2025 and completed one structured interview, generally after delivery, from January through July 2026. Exact vaccination-to-interview intervals were unavailable. Frequencies and Wilson 95% confidence intervals were calculated.
RESULTS: Of 225 completed questionnaires, 200 met the eligibility criteria. The mean maternal age was 28.1 years (standard deviation = 6.4). Any reaction was reported by 55.5% (95% CI: 48.6%-62.2%), most often injection-site pain (48.0%), and self-reported fever occurred in 2.5%. A participant-reported hypertensive disorder occurred in 12.0%. Four births were preterm (2.0%), and five newborns had low birth weight (2.5%). Participant-reported jaundice was the most frequent neonatal condition (20.0%).
CONCLUSIONS: Reported reactions were mainly local and short-lived. These findings describe early implementation in Panama but do not assess vaccine effectiveness, comparative safety, rare-event risk, or causality. Convenience recruitment, post-delivery selection, retrospective recall, absence of clinical verification and a comparator, and missing baseline risk and event-timing data limit interpretation.
METHODS: This retrospective descriptive cohort included women aged 18 years or older who received RSVpreF at 32.0-36.6 weeks of gestation from July through December 2025 and completed one structured interview, generally after delivery, from January through July 2026. Exact vaccination-to-interview intervals were unavailable. Frequencies and Wilson 95% confidence intervals were calculated.
RESULTS: Of 225 completed questionnaires, 200 met the eligibility criteria. The mean maternal age was 28.1 years (standard deviation = 6.4). Any reaction was reported by 55.5% (95% CI: 48.6%-62.2%), most often injection-site pain (48.0%), and self-reported fever occurred in 2.5%. A participant-reported hypertensive disorder occurred in 12.0%. Four births were preterm (2.0%), and five newborns had low birth weight (2.5%). Participant-reported jaundice was the most frequent neonatal condition (20.0%).
CONCLUSIONS: Reported reactions were mainly local and short-lived. These findings describe early implementation in Panama but do not assess vaccine effectiveness, comparative safety, rare-event risk, or causality. Convenience recruitment, post-delivery selection, retrospective recall, absence of clinical verification and a comparator, and missing baseline risk and event-timing data limit interpretation.